An Open-Label Study to Assess the Effect of Dexpramipexole (BIIB050) on the Pharmacokinetics of Warfarin in Healthy Volunteers
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials
| City: |
|
Overland Park |
| State: |
|
Kansas |
| Zip Code: |
|
|
| Conditions: |
|
Healthy Volunteers |
| Purpose: |
|
This study will assess the effect of dexpramipexole on the pharmacokinetics (PK) of the
CYP2C9 probe substrate warfarin in healthy volunteers.
|
| Study Summary: |
|
This is a single center open label study to assess the effect of Dexpramipexole on the PK of
Warfarin in Healthy Volunteers. The goals of this study are as follows: to assess the
effect of dexpramipexole on the pharmacodynamics (PD) of warfarin, to assess the safety and
tolerability of dexpramipexole when administered alone, and with warfarin, and to assess the
PK of dexpramipexole when administered alone; to explore the influence of genetic variation
on the PK and international normalized ratio (INR) of warfarin when administered alone, and
with dexpramipexole; and to explore the influence of genetic variation on the PK of
dexpramipexole when administered alone.
|
| Criteria: |
|
Inclusion Criteria:
- Subjects who, in the opinion of the investigator, are healthy as determined by
medical history, physical examination, and 12 Lead ECG.
- Adult males/females aged 18 to 55 years inclusive.
- Male and female subjects of childbearing age must practice effective contraception
during the study and up to 90 days after their last dose of study drug.
Exclusion Criteria:
- History of malignant disease, including solid tumors and hematologic malignancies.
- Clinically significant current active infection or serious infection.
- History of gastrointestinal bleeding, peptic ulcer disease, hemorrhoids or epistaxis.
- Personal or family history of any bleeding disorder, and/or coagulation profile
results outside of normal limits.
- Known allergy or hypersensitivity to warfarin.
|
| NCT ID: |
|
NCT01597310 |
| Primary Contact: |
|
N/A |
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Overland Park, Kansas United States
There is no listed contact information for this specific location.
Site Status: N/A |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 21, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|